Renesas supports FDA-authorised at-home COVID-19 test
Renesas has announced that it is delivering a synchronous boost converter solution in high volume for at-home COVID-19 test authrosied by the US Food and Drug Administration (FDA). Renesas prioritised a ramp-up for this kit to meet anticipated high demand.
Testing is a key weapon in the fight against COVID-19 with over 600 million tests administered in the US so far this year. The FDA issued an Emergency Use Authorisation (EUA) to Lucira Health, a medical technology company focused on the development and commercialis ation of transformative and innovative infectious disease test kits, for its single-use, user-friendly Lucird COVID-19 All-In-One Test Kit that can produce a positive or negative result at home within 30 minutes. This is faster than labs that currently take up to about seven days to generate similarly accurate test results. Lucira’s test kit is differentiated by its simple ‘swab, stir and detect’ design.
“We’re particularly pleased to contribute to Lucira’s important COVID-19 self-testing kit,” said Kris Rausch, vice president of Americas Sales for the IoT and infrastructure business unit at Renesas.
“As part of our corporate-wide efforts, Renesas has prioritised customers and solutions that help society battle this global pandemic.”
“Delivering the first single-use, at-home, molecular test kit for COVID-19 was a tremendous achievment of which we are extremely proud,” said Erik T. Engelson, president and CEO.
“It’s a testament to our technology, as well as the dedication and speed of our team. We required the same exceptional technology and speed from our suppliers, and Renesas quickly ramped-up to deliver exactly what we needed.”
Renesas’ commitment to fighting COVID-19
Renesas delivers key solutions that help society deal with the current pandemic. Healthcare, air purification, air quality monitoring,networking and mobility solutions from Renesas are being employed by customers around the world to enable a “new normal.”